Moderna

Moderna

Price: 45.99

Company and Business Model

Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.

Investment Profile

The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
-8.15 Risk
Revenue QoQ — quarter-over-quarter revenue growth
-42.6%
EPS surprise
60.9% better than expected
20d volatility
4.5% stable
FMP / FinFeed data updated: 2026-06-06
Reco: Sell Potential: 30 Risk: 80 Updated: 2026-06-11 05:23
How recommendation works
Why AI thinks so:
Weak fundamentals and negative momentum signal high risk.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-11 05:23 Hold Sell scenario_deterioration
2026-06-05 02:43 Sell Hold Weak fundamentals offset by recent price momentum.
2026-06-03 02:47 Hold Sell scenario_deterioration
Analyst forecasts
Date Analyst Action Target Price Then
2026-05-04 13:36 UBS Target Raised 36 → 45 47.465
2026-05-04 12:36 RBC Capital Target Raised 35 → 38 46.87
2026-05-01 23:40 Goldman Sachs Target Raised 43 → 49 45.37
Moderna

Акции Moderna (биотехнологическая компания) выросли на 11% на фоне ожиданий конференции JPMorgan Healthcare

Акции биофармацевтической компании Moderna значительно выросли на фоне предстоящей конференции в области здравоохранения, которая пройдет на следующей неделе.
Moderna Pfizer

FDA может добавить самое сильное предупреждение о безопасности к вакцинам против Covid

12/12/2025, 07:31 PM economy Moderna Pfizer
Недавние новости сообщают о том, что FDA (Управление по контролю за продуктами и лекарствами США) может ввести самое серьезное предупреждение о безопасности для вакцин против COVID-19.